Context Therapeutics (CNTX) Cash from Investing Activities (2021 - 2026)

Context Therapeutics has disclosed Cash from Investing Activities across 5 years of filings, most recently posting -$37258.0 for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$37258.0, down 9.75% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.0 million (up 86.23% YoY), and the FY2025 annual result was -$2.0 million, up 86.22% from the prior year.
• Cash from Investing Activities came in at -$37258.0 for Q1 2026 at Context Therapeutics, up from -$2.0 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of -$1837.0 in Q2 2022 to a low of -$14.8 million in Q3 2024.
• The 4-year median for Cash from Investing Activities is -$37258.0 (2026), against an average of -$2.5 million.
• Across the five-year window, Cash from Investing Activities jumped 99.27% in 2022 and retreated 9.75% in 2026, its largest moves.
• Context Therapeutics' Cash from Investing Activities stood at -$500000.0 in 2022, then sank by 2851.46% to -$14.8 million in 2024, then jumped by 86.45% to -$2.0 million in 2025, then jumped by 98.14% to -$37258.0 in 2026.
• The last three Cash from Investing Activities figures came in at -$37258.0 (Q1 2026), -$2.0 million (Q4 2025), and -$33948.0 (Q1 2025), per Business Quant data.